Table 1.
Overall cohort characteristics and comparison of prostate multiparametric MRI vs non-MRI cohort
| Variable | Characteristic | Overall | No staging MRI | Staging MRI | P value |
|---|---|---|---|---|---|
| N (%) | 705 | 166 | 539 | ||
| Age (y) | Mean ± SD | 67.1 ± 7.9 | 70.7 ± 7.8 | 65.9 ± 7.6 | <.001 |
| Race | White | 427 (60.6) | 84 (50.6) | 343 (63.6) | <.001 |
| Black | 231 (32.8) | 75 (45.2) | 156 (28.9) | ||
| Other | 47 (6.7) | 7 (4.2) | 40 (7.4) | ||
| Poverty | No | 521 (73.9) | 106 (63.9) | 415 (77.0) | <.001 |
| Yes | 184 (26.1) | 60 (36.1) | 124 (23.0) | ||
| Distance (miles) | <45 | 556 (78.9) | 142 (85.5) | 414 (76.8) | .016 |
| ≥45 | 149 (21.1) | 24 (14.5) | 125 (23.2) | ||
| Primary insurance | Private | 243 (34.5) | 42 (25.3) | 201 (37.3) | .005 |
| Nonprivate | 462 (65.5) | 124 (74.7) | 338 (62.7) | ||
| Treatment year | 2005-2007 | 159 (22.6) | 77 (48.4) | 82 (51.6) | <.001 |
| 2008-2009 | 129 (18.3) | 49 (38.0) | 80 (62.0) | ||
| 2010-2013 | 417 (59.1) | 40 (9.6) | 377 (90.4) | ||
| PSA (ng/mL) | Mean ± SD | 9.6 ± 14.2 | 10.5 ± 15.3 | 9.3 ± 13.8 | .351 |
| Gleason score | 6 | 290 (41.1) | 65 (39.2) | 225 (41.7) | .439 |
| 7 | 325 (46.1) | 75 (45.2) | 250 (46.4) | ||
| 8 | 52 (7.4) | 13 (7.8) | 39 (7.2) | ||
| 9 | 38 (5.4) | 13 (7.8) | 25 (4.6) | ||
| Clinical T stage | T1 | 502 (71.2) | 122 (73.5) | 380 (70.5) | .006 |
| T2 | 134 (19.0) | 38 (22.9) | 96 (17.8) | ||
| T3 | 69 (9.8) | 6 (3.6) | 63 (11.7) | ||
| Risk group | High | 151 (21.4) | 40 (24.1) | 111 (20.6) | .578 |
| Intermediate | 308 (43.7) | 68 (41.0) | 240 (44.5) | ||
| Low | 246 (34.9) | 58 (34.9) | 188 (34.9) | ||
| Percent positive biopsy cores | Mean ± SD | 0.4 ± 0.3 | 0.4 ± 0.3 | 0.4 ± 0.3 | .348 |
| IPSS | Mean ± SD | 7.9 ± 6.5 | 8.2 ± 6.1 | 7.8 ± 6.6 | .590 |
IPSS, International Prostate Symptom Score; MRI, magnetic resonance imaging; PSA, prostate-specific antigen; SD, standard deviation.